Refractory Chronic Cough
22
3
5
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
4.5%
1 terminated out of 22 trials
91.7%
+5.2% vs benchmark
18%
4 trials in Phase 3/4
64%
7 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (22)
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
Cough Management Wellness App for Refractory or Unexplained Chronic Cough
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
Group Telehealth Behavioral Cough Suppression Therapy
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)